Eterna Therapeutics (ERNA) Delisted from Nasdaq

TL;DR

**ERNA is getting delisted from Nasdaq, expect a major hit to liquidity and price.**

AI Summary

Eterna Therapeutics Inc. (ERNA) announced on January 17, 2024, that its common stock will be delisted from The Nasdaq Stock Market LLC. This delisting is due to the company's failure to meet continued listing standards, specifically the minimum bid price requirement. This matters to investors because it means their shares will no longer trade on a major exchange, likely reducing liquidity and potentially making it harder to sell their stock.

Why It Matters

The delisting of Eterna Therapeutics from Nasdaq will significantly reduce the stock's visibility and liquidity, making it much harder for investors to buy or sell shares.

Risk Assessment

Risk Level: high — Delisting from a major exchange like Nasdaq significantly increases investment risk due to reduced liquidity and potential price volatility.

Analyst Insight

A smart investor would consider selling any existing ERNA shares to avoid further losses due to decreased liquidity and potential price erosion following the Nasdaq delisting.

Key Players & Entities

• Eterna Therapeutics Inc. (company) — the registrant whose stock is being delisted
• The Nasdaq Stock Market LLC (company) — the exchange from which Eterna Therapeutics Inc. is being delisted
• January 17, 2024 (date) — the date of the earliest event reported regarding the delisting
• ERNA (company) — the trading symbol for Eterna Therapeutics Inc.

Forward-Looking Statements

• Eterna Therapeutics Inc. stock will experience a significant drop in trading volume and price. (ERNA) — high confidence, target: Q1 2024
• The company may seek to list its shares on an over-the-counter (OTC) market. (Eterna Therapeutics Inc.) — medium confidence, target: Q2 2024

FAQ

Key Financial Figures

• $0.005 — ich registered Common Stock, par value $0.005 per share ERNA The Nasdaq Stock Mar

Filing Documents

• ef20019104_8k.htm (8-K) — 25KB
• 0001140361-24-002915.txt ( ) — 158KB
• erna-20240117.xsd (EX-101.SCH) — 4KB
• erna-20240117_lab.xml (EX-101.LAB) — 22KB
• erna-20240117_pre.xml (EX-101.PRE) — 16KB
• ef20019104_8k_htm.xml (XML) — 4KB

01

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 17, 2024, Eterna Therapeutics Inc. (the "Company") received a notice (the "Notice") from the Listing Qualifications Staff ("Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that, due to the appointment of Dorothy Clarke as the Company's General Counsel, Ms. Clarke's subsequent resignation from the committees of the Company's Board of Directors (the "Board") and the appointment of Sanjeev Luther as a member of the Board, the Company no longer complies with Nasdaq's majority independent board and independent audit committee requirements as set forth in Nasdaq Listing Rule 5605. This rule, in relevant part, requires that (i) a board consist of a majority of independent directors and (ii) the audit committee consist of at least three members, each of whom must be an independent director under the Nasdaq Listing Rules and meet the heightened independence standards for audit committee members under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. The Notice indicates that Nasdaq is providing the Company with 45 days to submit a plan (the "Plan") to regain compliance. If Nasdaq accepts the Plan, then Nasdaq may, in its discretion, grant an extension of up to 180 calendar days from January 17, 2024 to regain compliance. In the event the Company does not regain compliance prior to the expiration of the applicable compliance period, the Nasdaq Listing Rules require the Nasdaq's Staff to provide written notification to the Company that its securities will be delisted. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Notice has no immediate effect on the Company's Nasdaq listing, and its common stock will continue to be listed under the symbol "ERNA." The Company is evaluating potential director candidates and intends to regain compliance with the Nasdaq Listing Rule 5605 pr

View Full Filing

View this 8-K filing on SEC EDGAR